How Mynosys is Gearing Up to Take on Femto

How Mynosys Is Gearing Up to Take on Femto

Now that Mynosys Cellular Devices has received FDA 510(k) clearance for its Zepto Capsulotomy System for cataract surgery, the company is planning its US launch August 1 and has partnered with Precision Lens of Bloomington, MN, to distribute the platform, Mynosys CEO John Hendrick tells OIS Weekly. Mynosys is based in Fremont, CA. Zepto takes…

Read More

InnFocus

InnFocus, a Santen company, is pioneering novel surgical solutions for treating glaucoma. The company is positioned to be the first FDA approved minimally invasive stand-alone procedure for mild, moderate, and severe stage open angle Glaucoma, that lowers and sustains IOP under 15 mmHg, and completely eliminates eye drop medications in most patients. The Company is…

Read More

Alcon’s Suite Approach to Building the Premium Channel

As cataract patients’ expectations rise, demanding visual performance on par with refractive surgery, Alcon is striving to meet those high expectations through its Cataract Refractive Suite, Seba Leoni, vice president and global head, Surgical Suite for Alcon reported during the panel on diagnostics and the premium channel at OIS@ASCRS 2016. Leoni quoted results that showed…

Read More

InnFocus Targeting Trabeculectomy

InnFocus’ MicroShunt is the only micro-invasive glaucoma surgery (MIGS) device undergoing a randomized clinical trial that uses trabeculectomy as the comparator. “We want to get to a point where trabeculectomy is really out of the market,” said Russ Trenary, president and CEO. “The stand-alone market is the place to be.” The glaucoma surgical procedure market…

Read More

Thompson Sees Huge Influx of New Refractive Tech

Vance Thompson, MD is an internationally recognized specialist in Laser Vision Correction and Advanced Cataract Surgery. As a leading international researcher he has played a key role in the development of the most advanced technologies and techniques for both laser and implant vision correction. Dr. Thompson led our Refractive Correction – Corneal & Intraocular Breakfast…

Read More

Iridex Makes its Move in Glaucoma

Iridex Makes Its Move in Glaucoma - Eye On Innovation Article

Over the past couple of years, there has been no shortage of positive news about the glaucoma space. While minimally invasive glaucoma surgery (MIGS) has totally captured the limelight, Iridex Corp. has quietly begun to build momentum with its Cyclo G6 laser. Iridex has a more than 30-year track record in laser photocoagulation and a…

Read More

Orca Aggressively Pursues Cataract Surgery Market

Yariv Bar-On, CEO of Orca Surgical, explains how his company is trying to change how surgeons remove the corneal epithelium during ophthalmic laser surgery. Orca says its flagship Epi Clear dynamic epikeratome device will introduce a “new paradigm for laser-assisted refractive surgery that is safer and less painful than existing microkeratome flap keratomileusis and advanced…

Read More

IOPtima Getting Traction in Europe, Asia

IOPtima CEO Ronan Castro gives OISTV an update on the company’s commerical launch of the IOPtimate system in Europe and Asia, including operations in China and Hong Kong. OPtima has developed the IOPtimate system; a unique laser based surgical system for the treatment of Glaucoma. The system utilizes a CO2 laser technology to reduce internal…

Read More

Is Auris Still Building a Robot for Cataract Surgery?

Auris Surgical Robotics Inc., a Bay Area medical technology company that had been developing a robotic platform for cataract surgery, just raised $150 million, but is in “stealth” mode as to what the proceeds of the capital infusion will be used for. David Schumer, head of marketing for Auris, would neither confirm nor deny reports…

Read More

Sharklet Technologies

Sharklet Technologies has incorporated technology derived from the shark’s ability to remain bacteria-free into a patterned protective membrane. To date, there is “strong in vivo results” showing the lens can facilitate the growth of human lens epithelial cells outside the visual axis, thus eliminating PCO. In lab analyses, when there is a smooth surface, cells…

Read More

Plenary Talk: Valeant’s Approach to Innovation

Valeant Pharmaceuticals is undergoing increased scrutiny. A year ago, J. Michael Pearson, then president and CEO, laid out the company’s vision for developing new tools in ophthalmology. Presenter: J. Michael Pearson Mr. Pearson has been the CEO and serving on the Board since September 2010 and the Chairman of the Board since March 2011. View…

Read More

WaveTec CEO Tom Frinzi Hints at Plans for Future

WaveTec CEO Tom Frinzi spoke to the ease of the deal that paired his company with Alcon, hints at plans for the future and explains how the Ophthalmology Innovation Summit aided the process of turning around the once troubled company. Speaking With: Tom Frinzi Thomas Frinzi is Senior Vice President of Abbott’s vision business, which…

Read More